{
    "Case ID": "020158",
    "Crime_Name": [
        "Patent Infringement Dispute"
    ],
    "Crime_Type": [
        "Property Crimes"
    ],
    "Dispute_Type": [
        "Patent Infringement Dispute"
    ],
    "Legal_Issue": [
        "Is Apotex's Notice of Allegation (NOA) sufficient to justify a conclusion of non-infringement of AstraZeneca's '794 Patent?"
    ],
    "Governing_Law": [
        "Patented Medicines (Notice of Compliance) Regulations"
    ],
    "Procedural_Stage": [
        "Application to prohibit issuance of Notice of Compliance"
    ],
    "Evidence_Assessment": [
        "No evidence provided by AstraZeneca showing amorphous tablets could result from crystalline material or that Apotex intended fraud"
    ],
    "Decision_Outcome": [
        "Dismissal of AstraZeneca's application"
    ],
    "Burden_of_Proof": [
        "On AstraZeneca to demonstrate potential infringement or abuse of process"
    ],
    "Credibility_Factor": [
        "AstraZeneca failed to provide convincing evidence"
    ],
    "Legal_Rule": [
        "A detailed statement in NOA must provide legal and factual basis for non-infringement"
    ],
    "Standard_of_Review": [
        "Sufficiency of NOA under regulatory requirements"
    ],
    "Procedural_Issue": [
        "Whether the NOA meets regulatory standards for detail and clarity"
    ],
    "Grounds_for_Claim": [
        "Alleged infringement of AstraZeneca's '794 Patent regarding magnesium omeprazole formulation"
    ],
    "Outcome_on_Merits": [
        "Apotex's NOA was sufficient; no abuse of process found"
    ],
    "Decision_Maker": [
        "Federal Court"
    ],
    "Judicial_Review_Outcome": [
        "Application dismissed"
    ],
    "Review_Standard": [
        "Regulatory compliance with PM(NOC) Regulations"
    ],
    "Procedural_Fairness_Assessment": [
        "Apotex provided clear statement of intended product composition"
    ],
    "Key_Evidence_Considered": [
        "Nature of amorphous magnesium omeprazole in Apotex's formulation"
    ],
    "Legal_Framework": [
        "Patented Medicines (Notice of Compliance) Regulations"
    ],
    "Applicant_Challenge": [
        "AstraZeneca challenged sufficiency of NOA"
    ],
    "Court_Result": [
        "In favor of Apotex"
    ],
    "Legal_Rule_Source": [
        "Patented Medicines (Notice of Compliance) Regulations"
    ],
    "Standard_of_Proof": [
        "Preponderance of evidence"
    ],
    "Defendant_Response": [
        "Apotex asserted use of amorphous magnesium omeprazole only"
    ],
    "Evidence_Type": [
        "Factual assertions in NOA, lack of counterevidence from patentee"
    ],
    "Remedy_Requested": [
        "Order to prohibit Minister of Health from issuing NOC"
    ],
    "Outcome": [
        "Request denied"
    ],
    "Decision_Authority": [
        "Federal Court"
    ],
    "Remedy_Sought": [
        "Interim injunction preventing NOC until patent expiry"
    ],
    "Resolution_Mechanism": [
        "Judicial determination under PM(NOC) Regulations"
    ],
    "Legal_Provision": [
        "Patented Medicines (Notice of Compliance) Regulations"
    ],
    "Authority": [
        "Minister of Health, Federal Court"
    ],
    "Claimant_Status": [
        "Patent holder (AstraZeneca)"
    ],
    "Legal_Provision_Cited": [
        "Patented Medicines (Notice of Compliance) Regulations"
    ],
    "Grounds_for_Inadmissibility_or_Allegation": [
        "Insufficient evidence of infringement or fraudulent intent"
    ],
    "Applicable_Process": [
        "Section 6 of PM(NOC) Regulations â€“ NOA and judicial review"
    ],
    "Outcome_of_Review": [
        "NOA upheld as sufficient"
    ],
    "Pending_Relief_or_Application": [
        "Application for prohibition of NOC"
    ],
    "Jurisdiction": [
        "Federal Court of Canada"
    ],
    "Governing_Rule": [
        "Requirement for detailed statement in NOA under PM(NOC) Regulations"
    ]
}